2007 OPEN FORUM Abstracts
IMPACT OF HIGH-FLOW NASAL CANNULA ON RSV PATIENTS: A RETROSPECTIVE LOOK
P. A. Dailey1, J. Fitzgerald2
Background. Every year the pediatric population is insulted with Respiratory Syncytial Virus (RSV) which can have devastating long-term implications including increased mortality. It was our hypothesis that the implementation of the Fisher & Paykel Optiflowâ¢ High Flow Nasal Cannula had a positive impact on our RSV population. Methods. The Fisher & Paykel Optiflowâ¢ High Flow Nasal Cannula was implemented in 2006. Since we started using the system we have had countless anecdotal reports of a variety of benefits that ranged from rapid relief from an increased work of breathing to averted intubations. The administration of the high flow cannula had become standard of care for this patient population immediately following its inception. We took a retrospective look at the pediatric patients coded with an RSV diagnosis at discharge. We ran data for the years FY 2004 and FY 2005 (two years pre implementation) and FY 2006 and FY 2007 (2 years post implementation). Results. The data supported our hypothesis (Refer to the chart below). Average cost per patient was reduced from $22,203 in FY 2004 to $3681 in FY 2007, length of stay (LOS) was reduced from 20.58 days to 2.33 days and mortality was reduced from 8.38 to 0 for both FY 2006 and FY 2007.
Conclusions: The use of the Fisher and Paykel High Flow Nasal Cannula system may reduce patient cost, LOS, mortality and improve patient outcomes in the RSV patient. It also provides another non-invasive avenue of choice in the treatment of the RSV patient that is also user friendly and comfortable for the patient. Further investigation utilizing a controlled randomized study may support more conclusive data regarding the impact on other patient populations.